Understanding the risk factors for neuropathic (nerve) pain in adults with diabetes and/or who have received neurotoxic chemotherapy to treat cancer

Partnership for Assessment and Investigation of Neuropathic Pain: Studies Tracking Outcomes, Risks and Mechanisms: Dundee Epidemiology study - investigating risk factors and possible causes of neuropathic pain

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN12494732

Enrollment

174500

Registered

2022-11-11

Start date

2023-03-27

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuropathic pain in adults with diabetes and/or who have received potentially neurotoxic chemotherapy to treat cancer. Nervous System Diseases

Interventions

This study aims to identify and replicate genetic and environmental risk factors for developing neuropathic pain in adults with diabetes and/or who have received potentially neurotoxic chemotherapy to

Eligibility

Sex/Gender

All

Age

18 Years to 120 Years

Inclusion criteria

Inclusion criteria: 1. 18 years or older 2. Existing consent to be re-contacted. 3. Identified as being currently alive. 4. Currently has a phone number, email or postal address on file 5. AND EITHER: 5.1. Adults on the SHARE register with diabetes mellitus AND/OR who have received potentially neurotoxic chemotherapy for the treatment of cancer, OR 5.2. Adults on the GoDARTS register who responded to two questionnaires for the DOLORisk Dundee study (REC reference: 15/YH/0285).

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
1. Presence of neuropathic pain at baseline, 18 and 72 months, assessed using survey-based questionnaires including: 1.1.Chronic pain identification questionnaire (presence of pain, currently taking pain medication and duration) 1.2.Douleur Neuropathique en 4 questions [DN4] questionnaire 1.3.List of body sites 1.4.Michigan Neuropathy Screening Instrument [MNSI] (only those with diabetes) 1.5.European Organisation for Research and Treatment of Cancer - Chemotherapy-Induced 1.6.Peripheral Neuropathy 20-item questionnaire [EORTC-CIPN20] (only those who have received neurotoxic chemotherapy)	—

Measure

Time frame

1. Presence of neuropathic pain at baseline, 18 and 72 months, assessed using survey-based questionnaires including: 1.1.Chronic pain identification questionnaire (presence of pain, currently taking pain medication and duration) 1.2.Douleur Neuropathique en 4 questions [DN4] questionnaire 1.3.List of body sites 1.4.Michigan Neuropathy Screening Instrument [MNSI] (only those with diabetes) 1.5.European Organisation for Research and Treatment of Cancer - Chemotherapy-Induced 1.6.Peripheral Neuropathy 20-item questionnaire [EORTC-CIPN20] (only those who have received neurotoxic chemotherapy)

—

Secondary

Measure	Time frame
At baseline, 18 and 72 months, assessed using survey-based questionnaires: 1. Severity of pain: 1.1. Chronic Pain Grade (CPG) questionnaire 1.2. Brief Pain Inventory (average) 2. Quality of life: 2.1. EQ5D-5L questionnaire 3. Psychological health: 3.1. PROMIS Depression Score 3.2. PROMIS Anxiety Score 3.3. PROMIS Sleep Score 3.4. PROMIS Support 3.5. TIPI Personality questionnaire 3.6. Pain Catastrophising scale 3.7. Traumatic Experiences 4. Lifestyle: 4.1. Smoking questionnaire 4.2. Alcohol questionnaire 4.3. Saltin-Grimby Physical Activity Level Scale (SGPALS) 5. Demographics: 5.1. Age (years) 5.2. Gender 5.3. Ethnicity 5.4. Social Deprivation (SIMD) 5.5. Weight (kg) 5.6. Height (cm) 5.7. Years in full-time education 5.8. Working status 5.9. Household income 6. Clinical: 6.1. Diabetes/Chemotherapy Duration 6.2. Diabetes Type	—

Measure

Time frame

At baseline, 18 and 72 months, assessed using survey-based questionnaires: 1. Severity of pain: 1.1. Chronic Pain Grade (CPG) questionnaire 1.2. Brief Pain Inventory (average) 2. Quality of life: 2.1. EQ5D-5L questionnaire 3. Psychological health: 3.1. PROMIS Depression Score 3.2. PROMIS Anxiety Score 3.3. PROMIS Sleep Score 3.4. PROMIS Support 3.5. TIPI Personality questionnaire 3.6. Pain Catastrophising scale 3.7. Traumatic Experiences 4. Lifestyle: 4.1. Smoking questionnaire 4.2. Alcohol questionnaire 4.3. Saltin-Grimby Physical Activity Level Scale (SGPALS) 5. Demographics: 5.1. Age (years) 5.2. Gender 5.3. Ethnicity 5.4. Social Deprivation (SIMD) 5.5. Weight (kg) 5.6. Height (cm) 5.7. Years in full-time education 5.8. Working status 5.9. Household income 6. Clinical: 6.1. Diabetes/Chemotherapy Duration 6.2. Diabetes Type

—

Countries

Scotland, United Kingdom

Contacts

Public ContactHarry;Natalia Hebert;Dygas

;

h.hebert@dundee.ac.uk;NDygas002@dundee.ac.uk+44 1382383191;-

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Aug 9, 2026